Richard G. Bach, MD
September 5th, 2013
Rosiglitazone Revisited
Richard G. Bach, MD and John Ryan, MD
Richard G. Bach discusses his study group’s observational analysis of data from the BARI 2D trial regarding outcomes associated with rosiglitazone.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?